Gene therapy is a promising field of medicine that involves the use of genetic material to treat or cure diseases. It has the potential to offer a more effective and targeted approach to the treatment of various diseases, including genetic disorders, cancer, and infectious diseases.
The global gene therapy market is expected to grow at a compound annual growth rate (CAGR) of 33.3% from 2021 to 2028, reaching a value of USD 35.67 billion by 2028.One of the key drivers of the gene therapy market is the increasing prevalence of genetic disorders. Genetic disorders are caused by abnormalities in the DNA sequence, leading to a range of medical conditions such as cystic fibrosis, hemophilia, and sickle cell disease. Gene therapy offers a promising approach to the treatment of these disorders, as it involves the modification or replacement of genes to correct the underlying genetic defect.
Another important factor driving the gene therapy market is the increasing investment in research and development by both private and public organisations. This investment is leading to the development of new gene therapies and technologies that have the potential to transform the treatment of various diseases. For example, the development of adeno-associated virus (AAV) vectors has greatly enhanced the efficiency and safety of gene delivery to target cells.
The rising demand for personalised medicine is also driving the growth of the gene therapy market. Personalised medicine involves tailoring medical treatment to the individual characteristics of each patient, such as their genetic makeup, lifestyle, and environment. Gene therapy offers a promising avenue for personalised medicine, as it can be tailored to the specific needs of each patient based on their genetic profile.
In addition to these drivers, the gene therapy market is also being fueled by favorable regulatory policies and increasing awareness and acceptance of gene therapy among healthcare professionals and patients. The US Food and Drug Administration (FDA) has approved several gene therapies in recent years, including Luxturna for inherited retinal disease and Zolgensma for spinal muscular atrophy.
Despite the promising growth prospects of the gene therapy market, there are also several challenges that need to be addressed. One of the biggest challenges is the high cost of these therapies, which can make them inaccessible to many patients. In addition, there are still many technical and regulatory challenges that need to be overcome in order to bring these therapies to market.
In conclusion, the gene therapy market is a rapidly growing and promising field with the potential to transform the treatment of various diseases. While there are still many challenges that need to be addressed, the market is expected to continue growing in the coming years as new gene therapies and technologies are developed and approved by regulatory agencies.
Mantell Associates is a specialist Pharmaceutical and Life Sciences headhunting firm. To find out how we can assist with your business requirements, get in touch with us at +44 203 854 7723.
Sources:
"Global Gene Therapy Market Size, Share & Trends Analysis Report by Vector Type (Viral Vector, Non-viral Vector), by Indication (Cancer, Genetic Disorders, Others), by Region, and Segment Forecasts, 2021-2028." Grand View Research, June 2021.
"Gene Therapy: The Journey So Far and the Road Ahead." American Society of Gene & Cell Therapy, December 2019.
"Global Gene Therapy Market to Reach $35.67 Billion by 2028." Market Research Future, August 2021.
"Gene Therapy: A Promising Frontier in Medicine." Mayo Clinic Proceedings, August 2019.
"Gene Therapy Comes of Age." Nature, October 2015.